Insulin Biosimilars Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Global<br />
<strong>Insulin</strong> <strong>Biosimilars</strong><br />
<strong>Market</strong><br />
Share, Global Trends,<br />
Analysis, Research, Report,<br />
Opportunities,<br />
Segmentation and Forecast,<br />
2016-2026<br />
Future <strong>Market</strong> Insights<br />
www.futuremarketinsights.com<br />
sales@futuremarketinsights.com
Future <strong>Market</strong> Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting<br />
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,<br />
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.<br />
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.<br />
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and<br />
Retail.<br />
We have a global presence with delivery centers across India specializing in providing global research reports and country<br />
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.<br />
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for<br />
our client.<br />
Research Capabilities<br />
• Customized Research<br />
• Syndicated Research<br />
• Investment Research<br />
• Social Media Research<br />
Sector Coverage<br />
• Automotive and Transportation<br />
• Electronics, Semiconductor, and ICT<br />
• Retail and Consumer Products<br />
• Industrial Automation and Equipment<br />
• Chemicals & Materials<br />
• Food and Beverages<br />
• Services and Utilities<br />
• Energy, Mining, Oil, and Gas<br />
Customized<br />
Research<br />
Syndicated<br />
Research<br />
Investment<br />
Research<br />
Social Media<br />
Research<br />
Subscription Information<br />
For detailed subscription information please contact<br />
Hari. T (Sr. Manager - Global Business Development)<br />
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268<br />
Email: hari.t@futuremarketinsights.com
Report Description<br />
A new race has been initiated between biosimilar and branded drug manufacturers to<br />
gain maximum revenue share from insulin market. The upcoming three years are very<br />
crucial for insulin manufacturers, as most of the branded insulin are going to be off<br />
patent which would results into the loss of around US$53 Bn revenue for branded<br />
manufacturers in 2016. Generic manufacturers are expected to take smaller chunk of this<br />
amount owing to their local presence which would restrain them take share from other<br />
markets. In such dynamic situation, the original drug manufacturers are seeking for plan<br />
B to sustain their hold in the market. As a result, these companies are now integrated<br />
with biosimilar manufacturers through agreement, alliance. Moreover, legal troubles<br />
pertaining patent infringement is hampering the development insulin <strong>Biosimilars</strong>. In<br />
order to overcome such infringement issues, the companies are now collaborating with<br />
each other to develop biosimilars versions of insulin. Recent example of global<br />
collaboration agreement between Mylan N.V. and Momenta Pharmaceuticals, Inc. has<br />
provided a competitive advantage to Mylan by increasing the number of insulin<br />
biosimlars under development. This collaboration will capitalized Mylan’s existing<br />
portfolio of biologics and insulin analog development.<br />
<strong>Insulin</strong> <strong>Biosimilars</strong> <strong>Market</strong>: Drivers and Restraints<br />
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are<br />
expected to drive growth of insulin biosimilars market. Government authorities are also<br />
focusing on the approval of insulin biosimilars owing to substantial financial burden in<br />
terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine
Report Description<br />
Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal<br />
insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar<br />
insulin glargine has got approval through European Medicines Agency's (EMA's)<br />
Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to<br />
drive the growth of insulin Biosimilar market. However, <strong>Insulin</strong> patent protection rights<br />
and strong retaliation from the branded manufactures has restricted the growth of<br />
insulin biosimilar development.<br />
Request Free Report Sample @<br />
http://www.futuremarketinsights.com/reports/sample/rep-gb-1883<br />
<strong>Insulin</strong> <strong>Biosimilars</strong> <strong>Market</strong>: Segmentation<br />
The global market for insulin Biosimilar is segmented on the basis of disease indication<br />
and geography.<br />
On the basis of disease indication, the global insulin Biosimilar market is segmented as,<br />
• Type I Diabetes<br />
• Type II Diabetes<br />
<strong>Insulin</strong> <strong>Biosimilars</strong> <strong>Market</strong>: Overview<br />
Development of clinically proven insulin Biosimilar will pave the road for new entrants.<br />
The upcoming patent expiration of blockbuster insulin drugs will open a new avenue and
Report Description<br />
unprecedented opportunities for biosimilar development and manufacturing companies.<br />
The cost of insulin biosimilar is currently high owing to stringent adherence requirements<br />
in terms of complex regulations and manufacturing and operations. Prices of biosimilar<br />
drugs are expected decreased by an average of 20% as compared to branded drugs.<br />
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1883<br />
<strong>Insulin</strong> <strong>Biosimilars</strong> <strong>Market</strong>: Region-wise Outlook<br />
Geographically, the global insulin biosimilar market is segmented into regions namely,<br />
North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Excluding<br />
Japan, Japan, Middle East and Africa. Among all the regions, North America will continue<br />
to lead the global market for insulin biosimilars market due to high demand for insulin.<br />
Europe insulin market is expected to account for second largest share in global market<br />
primarily due to early approval for biosimilar which is expected to fuel the market<br />
growth. Asian companies are competing on the basis of price and has patient pool<br />
suffering diabetes. Hence, the Asia Pacific insulin biosimilar market is expected to witness<br />
fastest growth in overall market over the forecast period.<br />
<strong>Insulin</strong> <strong>Biosimilars</strong> <strong>Market</strong>: Key Players<br />
Key players operating in the global insulin biosimilar market are Eli Lilly & Co.,<br />
Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V. and others<br />
Browse Full Report@ http://www.futuremarketinsights.com/reports/insulin-biosimilarsmarket
Thank You!<br />
To know more about us, please visit our website:<br />
www.futuremarketinsights.com<br />
For sales queries or new topics email us on:<br />
sales@futuremarketinsights.com<br />
Future <strong>Market</strong> Insights: 616 Corporate Way, Suite 2-9018,<br />
Valley Cottage, NY 10989, United States<br />
T: +1-347-918-3531 | D: +1-845-579-5705
Change language